Acerus Announces Closing of Additional US$6.5 Million Financing From First Generation Capital

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Dec 18, 2019 07:00 am
TORONTO -- 

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced that it has closed the previously announced amendment and restatement of the US$5.0 million subordinated secured term loan facility previously entered into on July 19, 2019 between Acerus and First Generation Capital, Inc. (“First Generation”), a company affiliated with the Chairman of the Board of Directors of Acerus, to (i) increase the borrowed amount to US$11.5 million, (ii) extend the maturity date to June 30, 2021 and (iii) cap the total amount of interest payable to First Generation under the A&R Loan (including interest paid from the closing of the original US$5.0 million subordinated secured term loan facility) to an amount equal to Cdn.$1,696,266.44 (“the A&R Loan”). (1)

The other terms of the A&R Loan remain unchanged from the original facility. The A&R Loan will continue to be subordinated to the existing US$9.0 million facility with SWK Funding LLC (“SWK”) and, subject to the cap on the total interest payable described above, will bear interest at a rate per annum equal to the three-month London Inter-Bank Offered Rate, plus an applicable margin of 10.50%. Subject to the terms of the subordination and intercreditor agreement between First Generation and SWK, the A&R Loan will be repayable in full on June 30, 2021, will continue to be interest-only until maturity with regularly scheduled payments of interest to First Generation being permitted subject to certain conditions related to Acerus’ market capitalization and aggregate annual revenue, and can be prepaid in full or in part without penalty following repayment in full of indebtedness owing to SWK. The proceeds from the A&R Loan will be used for ongoing general working capital. A copy of the amended and restated promissory note covering the A&R loan will be filed, following the closing of the transaction, under the Company’s profile on SEDAR at www.sedar.com.

Closing the A&R Loan also fully satisfied the conditions of the previously announced waiver letter from SWK related to certain financial covenants for Q4 2019, namely the December 15, 2019 Unencumbered Liquid Asset covenant as well as the December 31, 2019 Adjusted EBITDA and Aggregate Revenue covenants contained in the credit agreement (the “SWK Waiver”).

About Acerus

Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health. The Company commercializes its products via its own salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.

Acerus’ shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.

Notice Regarding Forward-Looking Statements

Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, including with respect to the Company’s ability to repay its debts and meet its financial covenants, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 4, 2019 which is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

(1) A material change report was not filed at least 21 days prior to the closing of amended and restated subordinated secured term loan facility from First Generation Capital Inc. as the terms and conditions of such arrangements were not yet finalized at such time.

Robert Motz
Chief Financial Officer
[email protected]
(905) 817-8288

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).